ArticlePloS one2025
The effect of supply chain risks management practices on operational performance of pharmaceutical manufacturing companies in Addis Ababa, Ethiopia: Analytical cross-sectional study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges and Proposed Solutions for Optimizing the Pharmaceutical Supply Chain Using the WHO Health System Building Blocks Framework: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficient movement of pharmaceuticals through various stakeholders to reach customers in the appropriate quantity and at the right time is achieved through supply chain management. However, the intricate nature of supply chain processes poses tremendous supply chain risks and jeopardizing pharmaceutical manufacturing company's ability. Failure to address these risks can hinder the provision of high-quality health services. However, effective supply chain risk management can foster more resilient and efficient global supply chains. Therefore, this study aimed to investigate the effect of pharmaceutical supply chain risks management practices on operational performance of pharmaceutical manufacturing companies in Addis Ababa, Ethiopia.
methodsAnalytical cross-sectional study complemented with qualitative method was conducted at pharmaceutical manufacturing companies in Addis Ababa between May-August 2023. One hundred seventy two staffs working in four manufacturing companies included in the study. For quantitative part, pretested a self-administered five-point Likert scale questionnaire was used and analyzed using SPSS® -version 26. Assumptions of linear multivariate regression were checked and the level of significance determined at a 95% CI and p-value <0.05. Nine face to face in-depth interviews with key informants were conducted to gather the qualitative data, and the data were analyzed using thematic analysis technique.
resultThe study included 172 employees from four manufacturing companies, with a response rate of 97%. The regression analysis revealed that demand (β=-0.191, t = -4.162, p < 0.05) and supply side risks (β=-0.131, t = -2.015, p < 0.05) have a negative effect on the operational performance of manufacturing companies. Holding other variables constant, a one-unit increase in demand and supply side risks results in 19.1% and 13.1% lead to decrease in operational performance of manufacturing companies, respectively. Increasing costs of freight, shortage and fluctuating foreign exchange rate for currency, lack of logistics expertise and organized risks mitigation team were the major challenges for manufacturing company's operational performance.
conclusionDemand and supply side risks affected the supply chain performance of the manufacturing companies. Furthermore, the increasing costs of freight, shortage of foreign currency, lack of logistics expertise and organized risk mitigation team were the main bottleneck for pharmaceutical manufacturing company's performance. The study result suggests demand and supply side risks, increasing costs of freight; shortage foreign currency exchange rate and lack of logistics expertise in companies should be given attention by stakeholders to improve operational performance. Furthermore, understanding these risk factors can improve the operational performance of the pharmaceutical industry by influencing policy and industry practices in the larger framework of global supply chain risk management not only one country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.